Repros Thera. Announces That Proellex Significantly Reduced Pain In A U.S. Phase 2 Clinical Trial In Women With Moderate To Severe Endometriosis

Repros Therapeutics Inc. (NasdaqGM:RPRX) released positive results of its recently completed U.S. Phase 2 Proellex endometriosis trial. Proellex is an oral progesterone receptor modulator. This analysis will be used as the basis for a request for an “End of Phase II Meeting” with the FDA.

More: continued here

Filed under: Clinical Trials on January 14th, 2009